MedTrace Logo

A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer

NCT06585969 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2026-02-12

No results posted yet for this study

Summary

The objective of this trial, DBCG R25, will be to evaluate the effect of trastuzumab-deruxtecan versus standard of care on progression-free survival (PFS) in first-line for patients with non-Luminal A, ER-positive/HER2-negative metastatic breast cancer

Conditions

Interventions

DRUG

Trastuzumab deruxtecan (T-DXd)

Trastuzumab deruxtexan every three weeks

DRUG

Ribociclib with ET

Ribociclib with endocrine therapy

DRUG

Abemaciclib with ET

Abemaciclib with endocrine therapy

Sponsors & Collaborators

  • Danish Breast Cancer Cooperative Group

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2026-01-01
Completion
2026-01-01
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06585969 on ClinicalTrials.gov